Indication

As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.

Medicine details

Medicine name:
danicopan (Voydeya)
SMC ID:
SMC2675
Pharmaceutical company
Alexion Pharma UK Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
04 November 2024